Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.31 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 4/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713771 | 0.91 | MAPK14 (0.34) | MAPK14JAK2NTRK1KCNJ5KCNJ3 | |
| SCHEMBL6707756 | 0.91 | F10 (0.40) | MAPK14KCNJ5KCNJ3F10 | |
| SCHEMBL6710365 | 0.88 | KDM1A (0.39) | KDM1ALCKFYNLMNAMAPT | |
| SCHEMBL6710238 | 0.87 | MAPK14 (0.35) | MAPK14ALKJAK2NTRK1KDM1A | |
| SCHEMBL6707832 | 0.87 | ADRA2A (0.37) | MAPT | |
| SCHEMBL6708943 | 0.87 | MAPT (0.36) | KDM1ALCKFYNSMN1; SMN2LMNA | |
| SCHEMBL6711750 | 0.86 | KDM1A (0.39) | KDM1ALCKFYNLMNAMAPT | |
| SCHEMBL6710156 | 0.86 | KDM1A (0.38) | KDM1A | |
| SCHEMBL6918952 | 0.85 | MAPK14 (0.31) | MAPK14KCNJ5KCNJ3 | |
| SCHEMBL6919505 | 0.85 | F10 (0.36) | MAPK14KCNJ5KCNJ3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | MAPK14 2897/4885ALK 3005/4885JAK2 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.